Sarcoidosis market projected to grow through 2036 as therapies advance
AI Summary- DelveInsight published a sarcoidosis market report covering treatment trends, emerging drugs and forecasts.
- 2022–2036 is the report’s study period across seven major markets.
- Acthar Gel remains the only FDA-approved treatment specifically indicated for symptomatic pulmonary sarcoidosis.